NasdaqGM - Nasdaq Real Time Price USD

Prime Medicine, Inc. (PRME)

2.9000

+0.0700

+(2.47%)

As of 11:42:33 AM EST. Market Open.

Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine, will present a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 3:00 p.m. PT (6:00 p.m. ET) in San Francisco, CA. A live audio webcast of

GlobeNewswire 24 days ago

PRME
+2.47%
Is Prime Medicine (PRME) Among the Top CRISPR Stocks to Invest In?

We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where Prime Medicine, Inc. (NASDAQ:PRME) stands against the other CRISPR stocks. The pharmaceutical industry is buzzing with innovation, driven by the need for new treatments, tackling unmet medical challenges, and leveraging […]

Insider Monkey 30 days ago

PRME
+2.47%
Why Prime Medicine (PRME) Is One of the Best Biotech Penny Stocks to Invest in Now?

We recently published a list of the 12 Best Biotech Penny Stocks To Invest In Now. In this article, we are going to take a look at where Prime Medicine, Inc. (NASDAQ:PRME) stands against the other best biotech penny stocks to invest in now. Goldman Sachs has spotlighted an often-overlooked sector poised to benefit from […]

Insider Monkey last month

PRME
+2.47%
Prime Medicine, Inc. (PRME): Is This Gene Therapy Stock a Good Buy Right Now?

We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we are going to take a look at where Prime Medicine, Inc. (NASDAQ:PRME) stands against the other gene therapy stocks. Gene therapy is referred to as a medical technique that involves modifying or manipulating genes to treat or […]

Insider Monkey last month

PRME
+2.47%
Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Simply Wall St. 2 months ago

PRME
+2.47%
Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates

-- Presented initial in vivo data for universal liver-targeted LNP and Wilson’s Disease program at ESGCT; initiated IND-enabling activities for Wilson’s Disease program in 4Q 2024 and remains on track to file IND and/or CTA in 1H 2026 -- -- Announced strategic research collaboration and license agreement with Bristol Myers Squibb; received $110 million upfront, with potential for more than $3.5 billion in milestone payments -- -- On track to report initial data from Phase 1/2 clinical trial of P

GlobeNewswire 2 months ago

PRME
+2.47%
Prime Medicine to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in the following upcoming conferences: Guggenheim's Inaugural Healthcare Innovation Conference: Fireside chat on Wednesday, November 13, 2024, at 3:00 p.m. ET in Boston, MA.Stifel 2024 Healthcare Conference: Fireside chat on Monday, Novemb

GlobeNewswire 2 months ago

PRME
+2.47%
12 High-Growth Stocks That Could Deliver Parabolic Returns

These 12 innovative companies could deliver exponential returns over the next quarter century.

Motley Fool 3 months ago

PRME
+2.47%
Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

Delivery of Prime Editors with a proprietary, universal liver-targeted LNP was well tolerated, with no safety concerns or detectable off-target edits observed across multiple preclinical studies On track to initiate IND-enabling activities for Wilson’s Disease program in 4Q 2024, with IND and/or CTA filing expected in 1H 2026 CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-t

GlobeNewswire 3 months ago

PRME
+2.47%
Why I Keep Buying These 14 Incredible Growth Stocks

This diverse set of growth stocks offers tremendous opportunities in the fields of AI, space, biotech, and emerging industries.

Motley Fool 3 months ago

^GSPC

NVDA

CRSP
Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings

-- On-track to initiate IND-enabling activities for Wilson’s Disease program in 4Q 2024, with IND or CTA filing expected in 1H 2026 -- CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the Company will highlight advances from across its Prime Editing pipeline and platform at the upcoming European Society of Gene and Cell Therapy

GlobeNewswire 3 months ago

PRME
+2.47%
PRME Stock Rises 11.8% on Collaboration With Bristol Myers

Prime Medicine collaborates with Bristol Myers Squibb for the development of T-cell therapies. Shares gain.

Zacks 3 months ago

PRME
+2.47%
CELG-RT
BMS and Prime ink potential $3.5bn deal to develop T cell therapies

As part of the deal, which could be worth $3.5bn, BMS will gain developmental support and therapeutic reagents from Prime Medicine.

Pharmaceutical Technology 3 months ago

PRME
+2.47%
CELG-RT
Why Prime Medicine Stock Soared Nearly 12% Higher on Monday

Changes are afoot at the company, and investors welcomed them.

Motley Fool 3 months ago

PRME
+2.47%
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline

On Monday, Prime Medicine Inc. (NASDAQ:PRME) announced a strategic research collaboration and license agreement with Bristol Myers Squibb & Co (NYSE:BMY) to develop reagents for the next generation of ex vivo T-cell therapies. Under the terms of the agreement, Prime Medicine will design optimized Prime Editor reagents for a select number of targets, including reagents that use its Prime Assisted Site-Specific Integrase Gene Editing (PASSIGE) technology. Also Read: Preclinical-Phase Firm Prime Me

Benzinga 3 months ago

PRME
+2.47%
CELG-RT
Prime Medicine Unveils Strategically Focused Pipeline

-- Prioritizing Set of High Value Programs in Core Areas of Focus; Modularity of Prime Editing Platform Expected to Allow Prime Medicine to Generate Follow-on Candidates Rapidly and Efficiently -- -- Initial Clinical Data from Phase 1/2 Trial in CGD Expected in 2025 While Advancing Wilson’s Disease Program Toward Expected IND Application and/or CTA in 1H 2026 -- -- Today Announced Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multip

GlobeNewswire 3 months ago

PRME
+2.47%
Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies

Collaboration Combines Prime Medicine’s Precise, Multiplex Gene Editing Capabilities with Bristol Myers Squibb’s Broad Expertise in Development and Commercialization of Novel Cell Therapies Prime Medicine to Receive $110 Million Upfront, with Potential for More Than $3.5 Billion in Milestones, Including $1.4 Billion in Development Milestones and More Than $2.1 Billion in Commercialization Milestones CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME) today an

GlobeNewswire 3 months ago

BMY

CELG-RT

PRME
+2.47%
Prime to narrow gene editing research as it strikes deal with Bristol Myers

The high-profile biotech is zeroing in on programs that serve as proof points for its technology, while seeking partners for other assets.

BioPharma Dive 3 months ago

CELG-RT

PRME
+2.47%
2 Growth Stocks That Could Make You Richer

Discover two cutting-edge growth stocks that could revolutionize medicine and space exploration.

Motley Fool 5 months ago

PRME
+2.47%
Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates

CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the second quarter ended June 30, 2024, and provided a business update. “In the second quarter, we achieved a key milestone for Prime Medicine and our next-generation gene editing technology, securing clearance from the U.S. Food and Drug Administration (FDA)

GlobeNewswire 5 months ago

PRME
+2.47%

Performance Overview

Return	PRME	S&P 500
YTD	+4.32%	+3.43%
1-Year	-57.29%	+24.06%
3-Year	-84.71%	+37.86%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Prime Medicine, Inc. (PRME)

Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference

Is Prime Medicine (PRME) Among the Top CRISPR Stocks to Invest In?

Why Prime Medicine (PRME) Is One of the Best Biotech Penny Stocks to Invest in Now?

Prime Medicine, Inc. (PRME): Is This Gene Therapy Stock a Good Buy Right Now?

Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?

Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates

Prime Medicine to Participate in Upcoming Investor Conferences

12 High-Growth Stocks That Could Deliver Parabolic Returns

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson’s Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

Why I Keep Buying These 14 Incredible Growth Stocks

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson’s Disease, at Upcoming Scientific Meetings

PRME Stock Rises 11.8% on Collaboration With Bristol Myers

BMS and Prime ink potential $3.5bn deal to develop T cell therapies

Why Prime Medicine Stock Soared Nearly 12% Higher on Monday

Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline

Prime Medicine Unveils Strategically Focused Pipeline

Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies

Prime to narrow gene editing research as it strikes deal with Bristol Myers

2 Growth Stocks That Could Make You Richer

Prime Medicine Reports Second Quarter 2024 Financial Results and Provides Business Updates

Performance Overview